Addressing the pricing of diabetes drugs and improving access to affordable healthcare are critical to overcoming this challenge and ensuring broader access to necessary treatments across all socio-economic groups
Retatrutide 5 Mg Retatrutide (LY3437943) is an investigational peptide originally developed by Eli Lilly
In a different investigation, Michaelis et al
As Novo Nordisk and Lilly keep expanding their obesity portfolios, their respective new assets with novel MoAs, some of which are expected to enter the market in the next 3 years, will need to be optimally (co-)positioned, in the context of both each players own portfolio and against the wider market
For example, contactin-4 (CNTN4) was upregulated after GBS but not semaglutide
There may be patient-specific factors that contribute to eye disease, especially in patients who have a dramatic improvement in glycemic control. Advertisement She notes that she is interested to see how the increasing use of these drugs will change the landscape of diabetic retinopathy long-term